CGP11952 is primarily used in research settings to study the effects of beta-adrenergic receptor blockade. It is a selective beta-1 adrenergic receptor antagonist, making it valuable for investigating cardiovascular functions and conditions related to heart rate and contractility. Researchers utilize CGP11952 to explore its potential in managing hypertension and other cardiac disorders by examining its interaction with beta-1 receptors in the heart. Additionally, it serves as a tool in pharmacological studies to understand the mechanisms of beta-blockers and their therapeutic applications. Its specificity helps in distinguishing the roles of beta-1 receptors from other adrenergic receptor subtypes in various physiological processes.